Today is July 16, 2024. All times in Eastern Daylight Time.
Innate Pharma partage de nouveaux résultats concernant l’essai de Phase 1/2 mené par Sanofi évaluant le NK cell engager SAR443579/IPH6101 dans divers cancers du sang
06/17/2024 - 01:00 AM
BUSINESS WIRE
New Survey from Canva, MMA Global Finds Senior Marketers See Creative Output as a Top Priority, Despite Investment Gaps and Shrinking Talent Pool
06/17/2024 - 01:00 AM
BUSINESS WIRE
Cal Poly Releases First “Imagineering” Report to Anticipate Novel Scenarios for Outer Space Cyberattacks
06/17/2024 - 12:01 AM
BUSINESS WIRE
VCTC启动Plugfest以通过增强超宽带技术推进数字钥匙的发展
06/16/2024 - 09:00 PM
BUSINESS WIRE
VCTC Kicks Off Plugfest to Advance Digital Keys by Enhancing Ultra-Wideband Technology
06/16/2024 - 09:00 PM
BUSINESS WIRE
Celltrion präsentiert auf dem EULAR 2024 vielversprechende Ergebnisse der Phase-III-Studie für CT-P47, einem Biosimilar-Kandidaten von RoActemra® (Tocilizumab) bei Patienten mit rheumatoider Arthritis (RA)
06/16/2024 - 08:14 PM
BUSINESS WIRE
Celltrion laat veelbelovende resultaten zien in fase III-studie voor CT-P47, een biosimilar-kandidaat van RoActemra ® (tocilizumab) bij patiënten met reumatoïde artritis (RA) op EULAR 2024
06/16/2024 - 08:14 PM
BUSINESS WIRE
Celltrion présente à EULAR 2024 les résultats prometteurs d’une étude de phase III sur le CT-P47, un candidat biosimilaire de RoActemra® (tocilizumab), menée sur des patients atteints de polyarthrite rhumatoïde (PR)
06/16/2024 - 08:14 PM
BUSINESS WIRE
Celltrion presenta risultati promettenti all'EULAR 2024 nello studio di fase III per CT-P47, candidato biosimilare di RoActemra® (tocilizumab) in pazienti affetti da artrite reumatoide (AR)
06/16/2024 - 08:13 PM
BUSINESS WIRE
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
06/16/2024 - 05:00 PM
BUSINESS WIRE
1
...
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
« Previous
Next »